Eosinophilic Cellulitis Seems to Be Type 2 Inflammatory Disease
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 21, 2023 -- Eosinophilic cellulitis seems to be a type 2 inflammatory disease, with preferential activation of the Janus kinase (JAK)1/JAK2-signal transducer and activator of transcription (STAT)5 pathways, according to research published online June 21 in JAMA Dermatology.
Johanna Morot, from the Université Claude Bernard Lyon in France, and colleagues examined the nature of eosinophilic cellulitis inflammation and other cellular signal transduction pathways that are activated in the context of eosinophilic cellulitis in a case series from January 2018 to December 2021. Samples were included from 14 patients with eosinophilic cellulitis and eight healthy controls.
The researchers found that in eosinophilic cellulitis lesions, there was marked type 2 inflammation (chemokines CCL17, CCL18, and CCL26, and interleukin 13), with preferential activation of the JAK1/JAK2-STAT5 pathways. Complete clinical remission of skin lesions was observed after one month of baricitinib treatment in the one index patient with refractory eosinophilic cellulitis.
"These findings suggest that eosinophilic cellulitis is a type 2 inflammatory disease with preferential activation of the JAK1/JAK2-STAT5 pathways," the authors write. "Together with the clinical response to baricitinib, our data advocate for the development of JAK1/JAK2 targeting treatment approaches in eosinophilic cellulitis and other eosinophilic diseases."
Several authors disclosed ties to pharmaceutical companies, including Lilly, the manufacturer of baricitinib.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Evidence-Based Approach Recommended for Acute Pancreatitis Management
MONDAY, March 18, 2024 -- In a clinical guideline issued by the American College of Gastroenterology and published online in the March issue of the American Journal of...
One Hundred Seventeen Cases of MIS-C Identified During 2023
THURSDAY, March 14, 2024 -- In 2023, 117 cases of multisystem inflammation syndrome in children (MIS-C) were reported, with 26 percent of patients having onset during August to...
Rheumatology Workforce Increased 20 Percent From 2009 to 2019
THURSDAY, March 14, 2024 -- The overall number of clinically active rheumatology providers grew more than 20 percent during the last decade, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.